A review of dextromethorphan and bupropion (Auvelity™) for the treatment of agitation in Alzheimer’s disease
Rajesh R. Tampi, Kayla Murphy, Julia C. Golden, Haley Schuster, Robin Conyers
Drugs in Context October 7, 2026 DOI: 10.7573/dic.2026-6-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | Notes that dextromethorphan-bupropion (Auvelity) is the second FDA-approved medication for agitation in Alzheimer's disease dementia, after brexpiprazole, and the first non-antipsychotic approved for this indication. The editorial reviews available efficacy and adverse-effect data for this use without reporting specific results in the abstract. |
Abstract
Dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets (AuvelityTM) became the second medication to be approved by the FDA for the treatment of agitation in Alzheimer’s disease dementia after brexpiprazole. It also became the first non-antipsychotic medication to be approved for this specific indication. In this Editorial, the available data regarding the efficacy and adverse effects of this medication in the treatment of agitation in Alzheimer’s disease dementia are reviewed.